Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADAR1-siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
ADAR1-siRNA refers to small interfering RNA (siRNA) designed to sequence-specifically target and knock down the expression of Adenosine Deaminase Acting on RNA 1 (ADAR1). ADAR1 is an enzyme that catalyzes the deamination of adenosine to inosine (A-to-I editing) in double-stranded RNA (dsRNA) substrates. In laboratory and preclinical research settings, ADAR1-siRNA is widely utilized as a gene-silencing tool to investigate the biological roles of ADAR1, particularly its involvement in RNA editing, immune recognition, ribosome biogenesis, and oncogenic translation. Knockdown of ADAR1 using siRNA has been shown to induce type I interferon signaling, trigger apoptosis in various cancer cell lines, and sensitize tumors to therapies such as immune checkpoint blockade or RNA polymerase I inhibitors.
- Other names
- ADAR1 siRNAADAR-1 siRNAADAR 1 siRNAADAR1 small interfering RNAADAR-1 small interfering RNAADAR 1 small interfering RNAsiADAR1siADAR-1siADAR 1
02
Targets
ADAR (Adenosine deaminases acting on RNA (ADAR) family)
Beyond the preview
Go deeper on ADAR1-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADAR1-siRNA.